We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Read MoreHide Full Article
Key Takeaways
TEM posted $193.8M in Genomics revenues, up 89% YoY, driven by oncology test volume and pricing gains.
TEM added $63.5M to Genomics revenues from hereditary testing after acquiring Ambry Genetics.
TEM plans to launch xM liquid biopsy and Xh whole-genome tests, aiming to expand clinical adoption.
AI in healthcare company Tempus AI (TEM - Free Report) delivered $193.8 million in Genomics revenues in the quarter ended March 2025, which increased nearly 89% year over year. The business benefited from 20% volume growth in oncology tests (legacy Tempus clinical testing) and higher average revenue per test due to increased Medicare reimbursement rates. Additionally, hereditary testing contributed $63.5 million in Genomics revenues on 23% volume growth from the February acquisition of Ambry Genetics. Tempus is now building on that momentum with more promising developments.
The company’s new liquid biopsy assay, xM for treatment response monitoring (TRM), is set to be launched clinically in the coming months. Aimed at both clinicians and biopharma researchers, the test is designed to track changes in the quantitative tumor fraction timely while patients receive immune-checkpoint inhibitor (ICI) therapies. xM for TRM detects a molecular response to ICI within the first six weeks of treatment — a critical advantage, particularly for patients with advanced disease — and can significantly influence treatment decisions. We believe this positions the assay well for driving future Genomics growth.
Further, the company’s first whole-genome sequencing (WGS) test, Xh, is also set to be launched clinically by next year. The offering is designed to help clinicians detect all clinically relevant variants and advance the personalized treatment landscape, specifically in hematological oncology.
Tempus is also developing a companion diagnostic (CDx) test with Verastem Oncology (VSTM - Free Report) , having completed confirmatory testing in VSTM’s Phase 2 RAMP-201 clinical trial. The study evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC). And now, Tempus’ FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial.
Updates From TEM’s Genomic Peers
Guardant Health (GH - Free Report) demonstrated strong momentum in the first quarter of 2025, with oncology revenues growing 20% year over year on a 25% increase in test volumes. In May, GH launched the Guardant Hereditary Cancer test, which identifies genetic variants associated with cancer risk. Further, Guardant Health’s newly introduced, advanced molecular profiling test requires 40% fewer tissue slides than the industry norm, allowing testing of more patients with less precious tissue.
Exact Sciences (EXAS - Free Report) continues to gain from the robust international adoption of its Oncotype DX genomic test. EXAS’ tumor-informed molecular residual disease (MRD) test, Oncodetect, has been validated in predicting recurrence in stage II–IV colorectal cancer, confirming its role in supporting treatment and surveillance decisions. Exact Sciences launched Cologuard Plus, which features novel genetic biomarkers and is expected to reduce false positives by more than 40% compared to the original Cologuard test.
TEM’s Price Performance, Valuation and Estimates
Year to date, Tempus AI shares have surged 105.3% compared with the industry’s 28% growth.
Image Source: Zacks Investment Research
Tempus AI is trading at a forward 12-month Price-to-Sales (P/S) of 8.60X compared to the industry average of 6.02X. It carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Tempus AI’s 2025 earnings has been trending upward over the past 90 days.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Key Takeaways
AI in healthcare company Tempus AI (TEM - Free Report) delivered $193.8 million in Genomics revenues in the quarter ended March 2025, which increased nearly 89% year over year. The business benefited from 20% volume growth in oncology tests (legacy Tempus clinical testing) and higher average revenue per test due to increased Medicare reimbursement rates. Additionally, hereditary testing contributed $63.5 million in Genomics revenues on 23% volume growth from the February acquisition of Ambry Genetics. Tempus is now building on that momentum with more promising developments.
The company’s new liquid biopsy assay, xM for treatment response monitoring (TRM), is set to be launched clinically in the coming months. Aimed at both clinicians and biopharma researchers, the test is designed to track changes in the quantitative tumor fraction timely while patients receive immune-checkpoint inhibitor (ICI) therapies. xM for TRM detects a molecular response to ICI within the first six weeks of treatment — a critical advantage, particularly for patients with advanced disease — and can significantly influence treatment decisions. We believe this positions the assay well for driving future Genomics growth.
Further, the company’s first whole-genome sequencing (WGS) test, Xh, is also set to be launched clinically by next year. The offering is designed to help clinicians detect all clinically relevant variants and advance the personalized treatment landscape, specifically in hematological oncology.
Tempus is also developing a companion diagnostic (CDx) test with Verastem Oncology (VSTM - Free Report) , having completed confirmatory testing in VSTM’s Phase 2 RAMP-201 clinical trial. The study evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC). And now, Tempus’ FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial.
Updates From TEM’s Genomic Peers
Guardant Health (GH - Free Report) demonstrated strong momentum in the first quarter of 2025, with oncology revenues growing 20% year over year on a 25% increase in test volumes. In May, GH launched the Guardant Hereditary Cancer test, which identifies genetic variants associated with cancer risk. Further, Guardant Health’s newly introduced, advanced molecular profiling test requires 40% fewer tissue slides than the industry norm, allowing testing of more patients with less precious tissue.
Exact Sciences (EXAS - Free Report) continues to gain from the robust international adoption of its Oncotype DX genomic test. EXAS’ tumor-informed molecular residual disease (MRD) test, Oncodetect, has been validated in predicting recurrence in stage II–IV colorectal cancer, confirming its role in supporting treatment and surveillance decisions. Exact Sciences launched Cologuard Plus, which features novel genetic biomarkers and is expected to reduce false positives by more than 40% compared to the original Cologuard test.
TEM’s Price Performance, Valuation and Estimates
Year to date, Tempus AI shares have surged 105.3% compared with the industry’s 28% growth.
Image Source: Zacks Investment Research
Tempus AI is trading at a forward 12-month Price-to-Sales (P/S) of 8.60X compared to the industry average of 6.02X. It carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Tempus AI’s 2025 earnings has been trending upward over the past 90 days.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.